<p><strong>Indications &amp; Usage</strong></p>

<p>AGEX-SL 375 (Ceftriaxone 250 mg &amp; Sulbactam 125 mg) Injection is indicated for susceptible pathogens causing: Complicated intra-abdominal infections.</p>

<ul>
	<li>Recurrent Urinary Tract Infections (UTIs) since sensitivity of E coli to ceftriaxone alone maybe 74%.</li>
	<li>Endocarditis due to ESBL elaborated by the pathogens.</li>
	<li>Confirmed staphylococcal, K pneumoniae or P mirabilis infections.</li>
	<li>Acinetobacter (banumannii) spp infections like nosocomial meningitis.</li>
	<li>Gram negative infections in ICU patients: 97% maybe cross-resistant to ceftriaxone because of marked loss of ceftriaxone&#39;s activity on account of production of class A and C &szlig;-lactamases.</li>
	<li>Pediatric respiratory infections because H influenzae is a common pathogen, and nearly 15% are &szlig;-lactamases producers.</li>
	<li>Critically ill patients with any ceftriaxone-susceptible infecting pathogens.</li>
	<li>Elderly patients with comorbid illness.</li>
	<li>Neonatal septicemia.</li>
	<li>Nosocomial infections since these bacteria are frequently &szlig;-lactamases producers (especially ESBL).</li>
	<li>Necrotizing surgical site infection.</li>
	<li>Resistant plague infection.</li>
</ul>

<p><strong>Contraindications</strong></p>

<p>AGEX-SL is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics. In patients hypersensitive to penicillin, consider the possibility of allergic cross-reactions. The use of sulbactam is contraindicated in individuals with a history of hypersensitivity reactions to any of the penicillins.</p>

<p><strong>Special Precautions</strong></p>

<p>Pregnancy and lactation</p>

<p><strong>Other Drug Interactions</strong></p>

<p>With aminoglycosides: Concomitant administration may increase risk of nephrotoxicity.<br />
With heparin/warfarin: Concurrent use may cause marked hypoprothrombinemia and/or prolonged bleeding time.</p>

<p><strong>Dosage &amp; Administration</strong></p>

<p>Parenteral (IM/IV): Adults: 1-2 gm ceftriaxone per day as AGEX &ndash; SL IM / IV once daily (or in equally divided doses twice a day) depending up on the type and severity of the infection. The total daily dose of ceftriaxone should not exceed 4 gm.</p>

<p>AGEX-SL therapy should generally be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration is 4 to 14 days; in complicated infections longer therapy may be required. While treating infections caused by Streptococcus pyogenes, the therapy should be continued for at least ten days.</p>

<p>Surgical Prophylaxis: 1 gm ceftriaxone single dose as AGEX &ndash; SL IV &frac12; to 2 hours before surgery.<br />
Uncomplicated Gonococcal Infections: 250 mg ceftriaxone single dose as AGEX &ndash; SL IM.<br />
Children: 50 to 75 mg ceftriaxone/kg body-weight per day (not exceeding 2 gm) as AGEX &ndash; SL IM / IV in 2 divided doses every 12 hours.</p>

<p>Meningitis: 100 mg ceftriaxone/kg body-weight per day (not exceeding 4 gm) as AGEX &ndash; SL IV initially; thereafter, 100 mg ceftriaxone/kg body-weight per day (maximum 4 gm/day) as AGEX- SL IV as single dose or in equally 2 divided doses every 12 hours for 7-14 days.</p>

<p>Acute Bacterial Otitis Media: 50 mg ceftriaxone/kg body-weight per day (not exceeding 1 gm) as AGEX &ndash; SL IM single dose.</p>

<p><strong>Presentations</strong></p>

<p>AGEX-SL 350<br />
Twin pack: Vial &amp; sterile water for injection as diluents.</p>
